US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

1.90

-0.0600-3.06%

Post-market: 1.970.0700+3.68%19:52 EDT

Volume:940.28K

Turnover:1.89M

Market Cap:115.37M

PE:-2.87

High:2.15

Open:2.00

Low:1.87

Close:1.96

52wk High:4.44

52wk Low:0.4100

Shares:60.72M

Float Shares:54.29M

Volume Ratio:0.85

T/O Rate:1.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6627

EPS(LYR):-1.2136

ROE:-418.06%

ROA:-60.16%

PB:6.99

PE(LYR):-1.57

Loading ...

Overview Company News Filings

Tuhura Biosciences Shares Fall 38.5% After $15.6 Million Direct Stock Deal

THOMSON REUTERS

BUZZ-TuHURA Biosciences plunges after $15.6 million direct stock deal

Tuhura Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

THOMSON REUTERS

TuHURA Biosciences Unveils Delta Opioid Receptor Inhibitor to Overcome Cancer Immunotherapy Resistance

Tuhura Biosciences Presents Data Demonstrating the Delta Opioid Receptor (Dor) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57TH Ash Annual Meeting and Exposition

THOMSON REUTERS

Tuhura Biosciences Secures Additional $1.5 Million Loan and Issues Warrants to Lender

Tuhura Biosciences Completes Private Placement of Common Stock and Warrants

Tuhura Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing

TuHURA Biosciences Is Maintained at Buy by Maxim Group

TuHURA Biosciences price target lowered to $8 from $15 at Maxim

TuHURA Biosciences Q3 EPS $(0.14) Beats $(0.15) Estimate

TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial

Press Release: TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

BRIEF-TuHURA Biosciences Signs ATM Deal With H.C. Wainwright To Sell Stock Worth Up To $50 Million – SEC Filing

Tuhura Biosciences Inc: Entered Into Atm Agreement With H.c. Wainwright to Sell Shares of Common Stock for Price of up to $50 Mln - SEC Filing

THOMSON REUTERS

BRIEF-Tuhura Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing

TuHURA Biosciences files $250M mixed securities shelf

Tuhura Biosciences Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS

TuHURA Biosciences Unveils Breakthrough Delta Opioid Receptor Targeting for Cancer Immunotherapy at ASH Meeting

TuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HURA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.9,"timestamp":1773432000000,"preClose":1.96,"halted":0,"volume":940282,"hourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.9,"latestTime":"19:52 EDT","volume":11313,"amount":21591.9068,"timestamp":1773445975105,"change":0.07,"changeRate":0.036842,"amplitude":0.052158},"delay":0,"changeRate":-0.03061224489795921,"floatShares":54286373,"shares":60720508,"eps":-0.662671,"marketStatus":"Closed","change":-0.06,"latestTime":"03-13 16:00:00 EDT","open":2,"high":2.15,"low":1.87,"amount":1885930.0013176,"amplitude":0.142857,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.662671,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.96,"preHourTrading":{"tag":"盘前","latestPrice":1.9896,"preClose":1.96,"latestTime":"09:19 EDT","volume":210,"amount":413.991585,"timestamp":1773407973405,"change":0.0296,"changeRate":0.015102,"amplitude":0.040816},"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.9,"latestTime":"19:52 EDT","volume":11313,"amount":21591.9068,"timestamp":1773445975105,"change":0.07,"changeRate":0.036842,"amplitude":0.052158},"volumeRatio":0.850595},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":54286373,"roa":"-60.16%","roe":"-418.06%","lyrEps":-1.213628,"volumeRatio":0.850595,"shares":60720508,"dividePrice":0,"high":2.15,"amplitude":0.142857,"preClose":1.96,"low":1.87,"week52Low":0.41,"pbRate":"6.99","week52High":4.44,"institutionHeld":0,"latestPrice":1.9,"eps":-0.662671,"divideRate":0,"volume":940282,"delay":0,"ttmEps":-0.662671,"open":2,"prevYearClose":0.7567,"prevWeekClose":1.5,"prevMonthClose":1.67,"prevQuarterClose":0.7567,"fiveDayClose":1.5,"twentyDayClose":1.39,"sixtyDayClose":0.9634},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1755316800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-03-12","current":-2.867184,"percent":0.744868,"low":-15.284879,"twenty":-8.271099,"median":-5.00053,"eighty":-3.4127,"high":-0.912265,"avg":-5.804844,"sd":3.00383,"marketCap":121441016},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-20","current":-2.301396,"twenty":-8.352484,"median":-5.119354,"eighty":-3.87886,"marketCap":67399763},{"date":"2026-02-27","current":-3.358794,"twenty":-8.340447,"median":-5.054798,"eighty":-3.490101,"marketCap":98367222},{"date":"2026-03-06","current":-3.234394,"twenty":-8.312748,"median":-5.017712,"eighty":-3.42514,"marketCap":94723992},{"date":"2026-03-12","current":-4.146659,"twenty":-8.271099,"median":-5.00053,"eighty":-3.4127,"marketCap":121441016}],"updateTime":1773448942584},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590340023","title":"Tuhura Biosciences Shares Fall 38.5% After $15.6 Million Direct Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590340023?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:02","pubTimestamp":1765296143,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2590285340","title":"BUZZ-TuHURA Biosciences plunges after $15.6 million direct stock deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2590285340","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590285340?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:56","pubTimestamp":1765295774,"startTime":"0","endTime":"0","summary":"BUZZ-TuHURA Biosciences plunges after $15.6 million direct stock deal** Drug developer TuHURA Biosciences' HURA.O shares plunge 36.9% to $1.25** HURA enters agreement for sale of ~9.5 million shares, Series A warrants, and Series B warrants in a registered direct offering at a purchase price of $1.65 apiece for gross proceeds of $15.6 million** H.C. Wainwright is the exclusive lead placement agent for offering** Closing of the offering is expected to occur in three tranches** Proceeds from the offering will be used for working capital and general purposes** All three analysts covering the stock rate it \"buy\"; median PT $9.13 - data compiled by LSEG** As of last close, HURA stock down 51.6% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3CF3QU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2590099342","title":"Tuhura Biosciences, Inc. Announces $15.6 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590099342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590099342?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:50","pubTimestamp":1765291801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA92V3GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2589635845","title":"TuHURA Biosciences Unveils Delta Opioid Receptor Inhibitor to Overcome Cancer Immunotherapy Resistance","url":"https://stock-news.laohu8.com/highlight/detail?id=2589635845","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589635845?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:50","pubTimestamp":1765198220,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. announced the presentation of new research on the Delta Opioid Receptor  as a novel target for overcoming acquired resistance to cancer immunotherapy. The results were presented at the 67th American Society of Hematology  Annual Meeting and Exposition. The company reported that DOR is expressed on tumor-associated myeloid-derived suppressor cells  and tumor-associated macrophages , and that inhibition of DOR reduces the immunosuppressive capabilities of these cells. TuHURA also highlighted the development of a library of selective and potent DOR antagonists and plans to advance a lead antibody drug conjugate  candidate consisting of a DOR inhibitor linked to a VISTA inhibiting antibody. The company stated that these ADCs have the potential to modulate the tumor microenvironment and support immune recognition of leukemic cells.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1MXxZf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2589358431","title":"Tuhura Biosciences Presents Data Demonstrating the Delta Opioid Receptor (Dor) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57TH Ash Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358431?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:50","pubTimestamp":1765198200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABTJ7WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2589359848","title":"Tuhura Biosciences Secures Additional $1.5 Million Loan and Issues Warrants to Lender","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359848?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:01","pubTimestamp":1764972083,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has amended its existing secured promissory note and loan agreement with the Matthew Nachtrab Revocable Trust. Under the amended terms, the lender extended the loan availability period to December 5, 2025, and provided Tuhura with an additional $1.5 million loan, bringing the total funds advanced to $3.0 million. In connection with the financing, Tuhura issued the lender a warrant to purchase 234,783 shares of common stock at an exercise price of $1.81 per share, with warrants allocated in proportion to amounts borrowed. The warrant will expire two years from the issuance date. No other material changes were made to the original loan agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8FFh48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2586473443","title":"Tuhura Biosciences Completes Private Placement of Common Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473443","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586473443?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:02","pubTimestamp":1764075739,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has completed a private placement with investors, involving the sale of shares of its common stock and warrants to purchase additional common stock. In connection with this transaction, the company registered the offer and sale of up to 9,321,545 shares, consisting of 4,570,629 shares of common stock and 4,750,916 shares issuable upon the exercise of warrants. The offer and sale of these shares will now be made from time to time under an effective Shelf Registration Statement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL4JXWGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2584692555","title":"Tuhura Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584692555","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584692555?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:27","pubTimestamp":1763569649,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - TuHURA Biosciences Inc ::*TUHURA BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-NOV-202523:03:20 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD3PyxHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2583860546","title":"TuHURA Biosciences Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2583860546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583860546?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:36","pubTimestamp":1763148960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 14:36 ET (19:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2583382685","title":"TuHURA Biosciences price target lowered to $8 from $15 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2583382685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583382685?lang=en_us&edition=fundamental","pubTime":"2025-11-15 01:20","pubTimestamp":1763140832,"startTime":"0","endTime":"0","summary":"Maxim lowered the firm’s price target on TuHURA Biosciences (HURA) to $8 from $15 and keeps a Buy rating on the shares. Published first on TheFly –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-8-from-15-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-8-from-15-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2583059485","title":"TuHURA Biosciences Q3 EPS $(0.14) Beats $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583059485","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583059485?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:39","pubTimestamp":1763123949,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 8.5 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48861351/tuhura-biosciences-q3-eps-0-14-beats-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","MNQmain","USJW.SI","QID","TSYW.SI","HURA","NQmain","USAW.SI","PSQ","TQQQ","SQQQ",".IXIC","QLD","BK4139"],"gpt_icon":0},{"id":"2583508058","title":"TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508058","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508058?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:01","pubTimestamp":1763121674,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc.  reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda  for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor  technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility follo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL74blBd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2583503836","title":"Press Release: TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503836","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583503836?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121600,"startTime":"0","endTime":"0","summary":"Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda  as a first-line therapy for advanced and metastatic Merkel cell carcinoma  is underway, conducted under Special Protocol Assessment  agreement with the U.S. Food and Drug Administration . Company's Delta Opioid Receptor  technology selected for an oral presentation, along with 2 poster presentations at the 67 Annual American Society of Hematology  Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025. TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended September 30, 2025, and provided a corporate update.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","BK4559","LU0203347892.USD","IE00BBT3K403.USD","LU1069347547.HKD","BK4007","LU1571399168.USD","HURA","LU1941712348.USD","LU1093756325.SGD","LU0098860793.USD","SG9999015341.SGD","MRK","LU0965509101.SGD","LU0106261372.USD","IE00BLSP4452.SGD","LU0122379950.USD","LU1291159041.SGD","SG9999014575.USD","LU2461242641.AUD","LU0266013472.USD","LU1941712264.USD","IE00BLSP4239.USD","LU2106854487.HKD","SG9999001176.USD","LU1066051225.USD","LU2361044949.HKD","SG9999002232.USD","LU1057294990.SGD","LU0320765489.SGD","LU1066051498.USD","LU1116320737.USD","SGXZ57979304.SGD","BK4022","BK4585","LU0058720904.USD","SG9999001440.SGD","BK4232","LU2361045086.USD","R","LU1929549753.HKD","BK4550","IE00BJT1NW94.SGD","LU1699723380.USD","SG9999015358.SGD","LU1989771016.USD","BK4139","LU2468319806.SGD","ASH"],"gpt_icon":0},{"id":"2580973927","title":"BRIEF-TuHURA Biosciences Signs ATM Deal With H.C. Wainwright To Sell Stock Worth Up To $50 Million – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580973927","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580973927?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:42","pubTimestamp":1762260161,"startTime":"0","endTime":"0","summary":"BRIEF-TuHURA Biosciences Signs ATM Deal With H.C. Wainwright To Sell Stock Worth Up To $50 Million – SEC FilingNov 4  - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INC: ENTERED INTO ATM AGREEMENT WITH H.C. WAINWRIGHT TO SELL SHARES OF COMMON STOCK FOR PRICE OF UP TO $50 MILLION - SEC FILINGSource text: [ID:n0001193125-25-263523]Further company coverage: HURA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG15Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2580199736","title":"Tuhura Biosciences Inc: Entered Into Atm Agreement With H.c. Wainwright to Sell Shares of Common Stock for Price of up to $50 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580199736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580199736?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:22","pubTimestamp":1762258935,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG15Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2580822495","title":"BRIEF-Tuhura Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580822495","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580822495?lang=en_us&edition=fundamental","pubTime":"2025-11-04 07:03","pubTimestamp":1762211000,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC FilingNov 4  - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILINGSource text: [ID:n0001193125-25-262843]Further company coverage: HURA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF24N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2580221439","title":"TuHURA Biosciences files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2580221439","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580221439?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:35","pubTimestamp":1762209314,"startTime":"0","endTime":"0","summary":"17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-files-250m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-files-250m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2580221396","title":"Tuhura Biosciences Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580221396","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580221396?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:32","pubTimestamp":1762209179,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF24N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2580219560","title":"TuHURA Biosciences Unveils Breakthrough Delta Opioid Receptor Targeting for Cancer Immunotherapy at ASH Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219560","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219560?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:02","pubTimestamp":1762178572,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. has announced that research on targeting the Delta Opioid Receptor  to reprogram myeloid-derived suppressor cells  has been accepted for oral presentation at the 67th American Society of Hematology  Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The presentation will highlight findings demonstrating DOR expression on tumor-associated MDSCs and tumor-associated macrophages , as well as the impact of DOR inhibition on their immunosuppressive functions. These results represent the first demonstration of DOR's role in these immune cells within the tumor microenvironment. Additional data, including a poster on the pathogenic role of DOR-expressing MDSCs in myelodysplastic syndrome , will also be presented at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9tg9zF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2580141944","title":"TuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust","url":"https://stock-news.laohu8.com/highlight/detail?id=2580141944","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580141944?lang=en_us&edition=fundamental","pubTime":"2025-11-01 05:01","pubTimestamp":1761944478,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL8VqVb3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}]}}